Niagen Bioscience (CDXC) Q1 2025 Earnings Call May 07, 2025 04:30 PM ET Speaker0 Ladies and gentlemen, thank you for standing by, and welcome to Niagen Biosciences Inc. First Quarter of twenty twenty five Earnings Conference Call. My name is Kayla, and I will be the conference operator today. At this time, all participants are in a listen only mode. And as a reminder, this conference call is being recorded. This afternoon, Niagen Bioscience issued a news release announcing the company's financial results fo ...

Niagen Bioscience, Inc. Earnings Presentation First Quarter 2025 Nasdaq: NAGE | May 7, 2025 SAFE HARBOR STATEMENT Q1 2025 & Recent Highlights Q1 2025 marked a strong start to the year, delivering impressive top- and bottom-line results and taking key steps toward building the future of Niagen Bioscience. (1) See slide 10 for the non-GAAP reconciliation This presentation and other written or oral statements made from time to time by representatives of Niagen Bioscience contain "forward-looking statements" wi ...

Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook Total net sales of $30.5 million, up $8.3 million or 38% year-over-year, gross margin of 63.4%, net income of $5.1 million and Adjusted EBITDA of $4.9 million for the three months ended March 31, 2025 and increased full year 2025 outlook. LOS ANGELES, CA - May 7, 2025 - Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the first quarter of 2025. Adjusted EBITDA, a non-GAAP measure, was $4.9 m ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Commission File Number: 001-37752 NIAGEN BIOSCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 26-2940963 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 10900 Wilshire Blvd. Suite 600, Los Angeles, California 90024 ...

ChromaDex Corporation (NASDAQ: CDXC ) is a bioscience company that concerns itself with cellular health and longevity, essentially, a fountain-of-youth kind of business of keeping cells ticking along as efficiently as possible for as long as possible. Their main focus is on developing andThe mission of Grassroots Trading rests on the following principles: providing objective, unbiased, and balanced research, backed by solid data and completely void of emotional influences or preference for companies; focusi ...

Financial Data and Key Metrics Changes - In Q4 2024, ChromaDex reported record revenues of $29.1 million, a 37% increase year-over-year, and net income of $7.2 million [9] - For the full year 2024, net revenues reached $99.6 million, reflecting a 19% growth year-over-year, with net income of $8.6 million, a significant turnaround from a net loss of $4.9 million in 2023 [9][23] - The company generated $12.1 million in positive cash flow from operations in 2024, ending the year with $44.7 million in cash and no debt [10][29] Business Line Data and Key Metrics Changes - E-commerce channel net sales were $17.3 million, a 30% increase year-over-year, while food-grade and pharmaceutical-grade Niagen ingredient sales reached $5.3 million, a 96% increase year-over-year [10][24] - Tru Niagen-related sales increased by 29%, driven by a 30% growth in e-commerce and a 26% increase in combined Watsons and other B2B sales [24] Market Data and Key Metrics Changes - The company noted a strong demand for NAD-boosting products, with a proliferation of companies entering the market, some of which engage in misleading practices [11][12] - The company is seeing increased awareness of NAD and Niagen, particularly following the launch of the Niagen IV product line [10][46] Company Strategy and Development Direction - ChromaDex plans to use its leadership position to drive consumer safety and product excellence, addressing misleading practices in the market [12][13] - The company is pursuing an investigational new drug application for the use of NR in treating ataxia telangiectasia and is working with the FDA on the NO-PARK study for Parkinson's disease [16][111] - A name change is anticipated to better align with the company's mission and strategic direction [17][34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, expecting approximately 18% growth in net sales for 2025, driven by e-commerce expansion and established partnerships [31] - The management highlighted the importance of addressing fraudulent practices in the NAD market and emphasized the need for regulatory action [12][106] Other Important Information - Gross margins improved to 61.8% for the full year, reflecting operational efficiency and a favorable product mix [23][25] - General and administrative expenses are expected to increase by approximately $5 million to $6 million in 2025, primarily due to investments in business growth [33][124] Q&A Session Summary Question: Can you discuss the stick packs and their performance? - The stick packs contain 300 milligrams and have seen increased sales, with plans for a marketing campaign in 2025 [36][37] Question: What is the expectation for the second payment from Elysium? - The second payment of $1.3 million from Elysium is expected by the end of March [40][41] Question: When can we expect results from the NO PARK study? - Results are anticipated around the end of Q3 or early Q4, but the company cannot guarantee public disclosure at that time [42][44] Question: How is the food-grade Niagen segment expected to perform in 2025? - The food-grade ingredient business is expected to continue growing, with new partnerships being added [46] Question: What drove the strong e-commerce performance in Q4? - Improvements in Shopify performance, increased awareness of NAD, and publicity contributed to the strong e-commerce results [54][55] Question: What are the supply chain risks associated with Niagen IV? - While there are always risks, the company believes it has resolved previous supply chain issues and is prepared for future demand [60][65] Question: How does the company view the potential market for NR adoption? - The company sees significant potential if the ongoing Parkinson's study yields positive results, with a large addressable market [111][116] Question: Will there be a spinout for pharmaceutical initiatives? - A spinout is a possibility if capital is insufficient for drug approval, but the company does not expect this to be necessary [119][121]

ChromaDex Earnings Conference Call Fourth Quarter 2024 Nasdaq: CDXC | March 4, 2025 SAFE HARBOR STATEMENT This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward- looking statements reflect the current view about future events. Statements that are not historical in na ...

ChromaDex Corporation (NASDAQ:CDXC) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Ben Shamsian - Vice President, Lytham Partners, Investor Relations Rob Fried - Chief Executive Officer Ozan Pamir - Chief Financial Officer Andrew Shao - SVP, Scientific & Regulatory Affairs Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Mitchell Pinheiro - Sturdivant Bill Dezellem - Tieton Capital Management Ram Selvaraju - H.C. Wainwright Sean McGowan - ROTH Capital J.P. Mark ...

分组1 - ChromaDex reported quarterly earnings of $0.03 per share, exceeding the Zacks Consensus Estimate of $0.02 per share, compared to break-even earnings per share a year ago, representing an earnings surprise of 50% [1] - The company achieved revenues of $29.13 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 7.47%, and showing an increase from year-ago revenues of $21.2 million [2] - ChromaDex has outperformed the S&P 500, with shares adding about 3.7% since the beginning of the year, while the S&P 500 declined by 0.5% [3] 分组2 - The current consensus EPS estimate for the coming quarter is $0.04 on revenues of $28.55 million, and for the current fiscal year, it is $0.12 on revenues of $120.8 million [7] - The Medical - Biomedical and Genetics industry, to which ChromaDex belongs, is currently in the top 29% of over 250 Zacks industries, indicating a favorable outlook for the sector [8]

Financial Performance - Full year net sales reached $99.6 million, a 19% increase from the prior year, with a gross margin of 61.8% and net income of $8.6 million[1][5][11] - Fourth quarter net sales were $29.1 million, up 37% year-over-year, with a gross margin of 62.5% and net income of $7.2 million, a significant improvement from $0.1 million in the prior year quarter[1][5][9] - Tru Niagen® sales contributed $22.7 million to fourth quarter net sales, reflecting a 29% increase from the prior year quarter[6][7] - Adjusted EBITDA for the full year was $8.5 million, a $6.6 million improvement from the previous year, while fourth quarter adjusted EBITDA was $3.4 million, up $2.1 million year-over-year[1][10][13] - Net sales for Q4 2024 reached $29,125,000, a 37.5% increase from $21,196,000 in Q4 2023[27] - Gross profit for Q4 2024 was $18,197,000, up 40.5% from $12,937,000 in Q4 2023[27] - Operating income for Q4 2024 was $7,111,000, compared to a loss of $168,000 in Q4 2023[27] - Net income for Q4 2024 was $7,179,000, a significant increase from $114,000 in Q4 2023[27] - Adjusted EBITDA for the full year 2024 was $8,504,000, compared to $1,900,000 in 2023, reflecting a substantial improvement[33] - The company reported a basic net income per share of $0.09 for Q4 2024, compared to a loss of $0.07 per share in Q4 2023[27] Cash and Assets - The company ended the year with $44.7 million in cash and no debt, with operating cash flows of $12.1 million, compared to $7.1 million in the prior year[1][14] - Cash and cash equivalents at the end of 2024 were $44,660,000, up from $27,325,000 in 2023, marking a 63.8% increase[31] - Total current assets increased to $64,102,000 in 2024 from $49,534,000 in 2023, representing a 29.3% growth[29] - Total liabilities decreased to $17,948,000 in 2024 from $20,622,000 in 2023, a reduction of 12.9%[29] Expenses and Projections - General and administrative expenses decreased by $6.6 million year-over-year, primarily due to lower royalty expenses and credit loss recoveries[1][16] - Selling and marketing expenses are expected to increase in absolute dollars but remain stable as a percentage of net sales, reflecting strategic investments in brand awareness[1][17] - Research and development expenses for the full year 2024 were $6,016,000, an increase from $4,958,000 in 2023[27] - For 2025, the company projects approximately 18% year-over-year revenue growth, with slight improvements in gross margin and increased general and administrative expenses of $5.0 to $6.0 million[1][17] Product Development and Regulatory - In 2024, ChromaDex launched Niagen Plus, a new product line featuring pharmaceutical-grade Niagen®, now available at over 475 wellness clinics in the U.S.[1][6] - The company received Orphan Drug and Rare Pediatric Disease Designations from the U.S. FDA for NR, and is advancing its Investigational New Drug application for Ataxia Telangiectasia[1][6]